NOVERA COMPOUNDS

PNC-28 20mg

PNC-28 is a synthetic peptide derived from p53 tumor suppressor protein (residues 17–26) fused with a penetratin sequence for cellular delivery. Laboratory models study their protein-membrane...

PNC-28 is a synthetic peptide derived from p53 tumor suppressor protein (residues 17–26) fused with a penetratin sequence for cellular delivery. Laboratory models study their protein-membrane interactions, cellular uptake mechanisms, and intracellular signaling pathways. Supplied as lyophilized powder in a sealed research-grade vial, it is manufactured to high purity via analytical testing for controlled experimental use.

10% off, code: PEPTEN
Purity Guarantee

PNC-28 20mg

Sign in to view pricing and purchase this product.

Log In Sign Up
Quantity Discount (%) Price
1 - 5 — $145.00
6 - 10 9.66 % $131.00
11 - 20 18.62 % $118.00
21+ 26.21 % $107.00

Why choose Novera Compounds peptides

Research-grade Quality

Every compound is manufactured to research-grade standards and intended strictly for laboratory and research use. Consistent quality you can build a reproducible protocol around.

Documented and traceable

  • Batch number on every vial

  • Published Certificates of Analysis

  • Purity verified by third-party testing

Handled and shipped with care

Temperature-sensitive compounds are stored and shipped under controlled conditions, so material arrives in the state your research requires. Expert support on hand at every step.

About the product

PNC-28 (20mg) is a synthetic peptide derived from a segment of the p53 tumor suppressor protein, specifically residues 17–26, and linked to a penetratin domain to facilitate cellular entry. This structure enables the peptide to be studied in laboratory environments focused on intracellular signaling and protein-membrane interactions.

The peptide is composed of a defined amino acid sequence designed to mimic functional aspects of p53-related signaling in controlled experimental systems.

Research-grade PNC-28 is typically produced with high purity and verified by HPLC and mass spectrometry. It is supplied as a 20 mg lyophilized powder in a sealed research-grade vial, commonly used in laboratory studies investigating cellular signaling, protein interaction mechanisms, and membrane-related processes.

PNC-28 (20mg) Key Features & Specs

  • Subcategory: Cellular Signaling & Protein Interaction Research Peptides
  • Strength: 20 mg
  • CAS Number: 392661-17-5
  • Chemical Formula: C₁₆₄H₂₅₅N₄₇O₃₇S
  • Molecular Weight: 3509.13 g/mol
  • Peptide Sequence: Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly
  • Synonyms: PNC28, PNC 28, p53 17-26 penetratin peptide

For laboratory research use only.

PNC-28 (20mg) Research Uses

PNC-28 (20mg) has been studied in laboratory environments focused on cellular signaling and protein-membrane interactions. Originating from the p53 protein, it is commonly used in research exploring how peptides interact with cellular structures and influence intracellular processes.

Research involving this peptide typically examines biological systems related to cellular communication, membrane interactions, and signaling pathways associated with protein function. These studies aim to understand how peptide fragments derived from regulatory proteins influence cellular behavior in controlled environments.

In experimental models, PNC-28 is used to investigate how signaling molecules interact with cellular membranes and intracellular pathways involved in protein-mediated signaling processes.

PNC-28 (20mg) Insights & Observed Findings

Preclinical and in vitro studies of p53-derived peptides like PNC-28 have evaluated activity across micromolar concentration ranges, depending on the experimental design and biological system. These studies are conducted to assess interactions between peptides and cellular components.

Animal studies investigating peptide-mediated signaling have reported dosing ranges in the microgram-per-kilogram (µg/kg) range. These parameters vary depending on the research model and objectives.

Observed findings suggest that p53-related peptides may modulate molecular pathways involved in cellular signaling, membrane interactions, and protein communication. These findings remain under investigation and should not be interpreted as evidence of clinical outcomes.

PNC-28 (20mg) Handling & Storage

  • Store lyophilized powder at 2–8 °C or –20 °C in a controlled environment, protected from light, heat, and moisture.
  • After reconstitution with sterile laboratory-grade solvent, store solution refrigerated (2–8°C).
  • Avoid repeated freeze-thaw cycles. Use aseptic technique and follow institutional biosafety guidelines.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

  1. Michl J, Scharf B, Schmidt A, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006;119(7):1577-1585. doi:10.1002/ijc.22029
  2. National Center for Biotechnology Information. PubChem Compound Summary for CID 16158363, Pnc-28. https://pubchem.ncbi.nlm.nih.gov/compound/Pnc-28.
  3. Bowne WB, Sookraj KA, Vishnevetsky M, et al. The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol. 2008;15(12):3588-3600. doi:10.1245/s10434-008-0147-0
  4. Pincus MR, Silberstein M, Zohar N, Sarafraz-Yazdi E, Bowne WB. Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells. Biomedicines. 2024;12(6):1144. Published 2024 May 22. doi:10.3390/biomedicines12061144